


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



INSILICO MEDICINE

**InSilico Medicine Cayman TopCo**

**英矽智能**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3696)**

## **VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Insilico Medicine**”) on a voluntary basis.

Reference is made to the announcement of the Company dated September 4, 2026. As notified by Mr. Zavoronkovs, chairman of the Board, an executive director, the chief executive officer, the chief business officer and the single largest shareholder of the Company, that from September 4, 2026 to September 7, 2026, he has purchased an aggregate of 113,500 ordinary shares of the Company (the “**Shares**”) through open market transactions with his own funds (the “**Share Purchases**”). Immediately after the Share Purchases, Mr. Zavoronkovs is entitled to exercise the voting rights of 46,757,000 Shares, representing approximately 8.02% of the Company’s total issued share capital.

The Share Purchases, representing the first tranche of purchases under Mr. Zavoronkovs’ Share Increasing Plan announced on September 4, 2026, were conducted in accordance with the notification and clearance procedures required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Mr. Zavoronkovs intends to acquire further Shares subject to, among others, the then market conditions and his investment plan. The Board believes that the voluntary acquisition of the Shares through purchases in the market by Mr. Zavoronkovs demonstrates his confidence in the long-term development and prospects of the Group.

Based on the information currently available to the Company and to the best knowledge and belief of the Directors, after making all reasonable inquiries, the Company has maintained sufficient public float of its issued shares as required by the Listing Rules after the Share Purchases.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**InSilico Medicine Cayman TopCo**  
**Mr. Aleksandrs Zavoronkovs, Ph.D.**  
*Chairman, Executive Director, CEO and CBO*

Hong Kong, September 14, 2026

*As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as a non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.*